UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 


 

FORM 8-K

 


 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): April 27, 2010

 


 

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

 


 

Delaware

 

000-30319

 

94-3265960

(State or Other Jurisdiction of
Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification Number)

 

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

(a)                                  The Annual Meeting of Stockholders of Theravance, Inc. was held on April 27, 2010.

 

(b)           The table below presents the results of the election to the Company’s board of directors.

 

 

 

Votes for

 

Votes withheld

 

Rick E Winningham

 

53,531,064

 

243,578

 

Jeffrey M. Drazan

 

35,871,470

 

17,903,172

 

Robert V. Gunderson, Jr.

 

52,818,471

 

956,171

 

Arnold J. Levine. Ph.D

 

37,123,809

 

16,650,833

 

Burton G. Malkiel, Ph.D.

 

53,620,797

 

153,845

 

Peter S. Ringrose, Ph.D.

 

53,644,830

 

129,812

 

William H. Waltrip

 

53,623,097

 

151,545

 

George M. Whitesides, Ph.D

 

52,114,309

 

1,660,333

 

William D. Young

 

52,843,922

 

930,720

 

 

The stockholders also approved the amendment and restatement of the Company’s 2004 Equity Incentive Plan. The table below presents the voting results:

 

 

 

Affirmative
Votes

 

Negative
Votes

 

Votes
Abstained

 

Approval of amendment and restatement of 2004 Equity Incentive Plan

 

43,001,578

 

10,771,639

 

1,425

 

 

The stockholders also ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010. The table below presents the voting results:

 

 

 

Affirmative
Votes

 

Negative
Votes

 

Votes
Abstained

 

Ratification of independent registered public accounting firm

 

58,892,703

 

184,450

 

4,111

 

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

THERAVANCE, INC.

 

 

 

 

 

 

Dated: April 30, 2010

By:

/s/ Rick E Winningham

 

 

Rick E Winningham

 

 

Chief Executive Officer

 

3